Clinical trials: Antibody
Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma
Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer
This phase II trial studies the effect of futibatinib and pembrolizumab in treating patients with FGF19 positive BCLC stage A, B, or C liver cancer that has spread to other parts of the body (advanced or metastatic).
- Conditions
- Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
- Trial name
- NCT04828486
- Testing
- Futibatinib, Pembrolizumab, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Mayo Clinic
Peripheral Spondyloarthritis
Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)
The objective of this study was to evaluate the efficacy and safety of adalimumab 40 mg administered every other week (eow) subcutaneously (SC) compared to placebo for 12 weeks followed by open label (OL) safety and efficacy…
- Trial name
- NCT01064856
- Testing
- Adalimumab
- Volunteers
- 165 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Amyloidosis
Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis
The investigators expect to enroll 15 participants with relapsed or refractory IgM-associated AL amyloidosis onto this Phase II clinical trial.
- Trial name
- NCT02590588
- Testing
- Idelalisib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- John Mark Sloan
Juvenile Idiopathic Arthritis
A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in patients who have active juvenile idiopathic arthritis (JIA) and at least 5 joints with active arthritis that have poor response to…
- Trial name
- NCT01230827
- Testing
- CNTO 148 (Golimumab), Methotrexate
- Where
- 35 sites in United States, Austria and 10 more
- Volunteers
- 173 people
- Sponsor
- Janssen Research & Development, LLC
Esophageal Squamous Cell Carcinoma
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
The study aimed to evaluate the efficacy and safety of sitravatinib in combination with tislelizumab as a second- or third-line treatment for participants with locally advanced, unresectable, or metastatic esophageal squamous…
- Trial name
- NCT05461794
- Testing
- Sitravatinib, Tislelizumab, Docetaxel
- Where
- 31 sites in China
- Volunteers
- 96 people
- Sponsor
- BeiGene
Healthy Participants
Washington University WU 409: Immune Responses to Rabies Vaccine.
This study will evaluate the immune response to rabies vaccination persons 18 years and older. We will evaluate thirty healthy participants across three cohorts: 1) standard rabies pre-exposure prophylaxis regimen (two doses of…
- Trial name
- NCT07399951
- Testing
- Imovax, RabAvert, HyperRAB
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
COVID-19
Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients
Introduction: Corona Virus induced disease - 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now.
- Trial name
- NCT05502081
- Testing
- Casirivimab and Imdevimab Drug Combination, Remdesivir, Favipiravir
- Where
- Egypt
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Mansoura University Hospital
Meningoccocal Disease, Meningococcal Meningitis
Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28
The aim of this extension study is to explore the antibody persistence 24 to 36 months after the last dose of vaccine, in infants that received a two or three dose primary series plus a booster dose at 11 months of age, of the…
- Trial name
- NCT01894919
- Testing
- Bexsero® vaccine (1 dose at study month zero), Bexsero® vaccine (2 doses 1 month apart)
- Where
- 17 sites in Hungary, Spain
- Volunteers
- 851 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Arthritis, Rheumatoid
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
A 3-year open-label trial for patients who previously participated in Trial Hx-CD20-403 and who fulfill the eligibility criteria for this trial (GEN413) .
- Trial name
- NCT00655824
- Testing
- ofatumumab
- Where
- 10 sites in United States, Denmark and 3 more
- Volunteers
- 124 people
- Sponsor
- GlaxoSmithKline
Meningitis, Meningococcal Infection
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®
The study is designed to evaluate the persistence of bactericidal antibodies in subjects aged 7 to 15 years (not yet 16 years) who had been vaccinated five years previously in Study 603-02.
- Trial name
- NCT00258856
- Testing
- Polysaccharide Diphtheria Conjugate Vaccine
- Where
- 11 sites in United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Virus Diseases
The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine
The purpose of this study is to continue the evaluation of antibody persistence through 11 to 15 years after first booster with Tick-Borne Encephalitis (TBE) vaccine.
- Trial name
- NCT03294135
- Testing
- Encepur Adults
- Where
- Czechia
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neoplasms
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
This is a Phase 1B/2, non-randomized, dose-escalation, multicenter, open-label study designed to evaluate the safety and tolerability of robatumumab (SCH 717454, MK-7454) in combination with standard treatment in participants…
- Trial name
- NCT00954512
- Testing
- Carboplatin, Epirubicin, Trastuzumab
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemia
LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy
To evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab (AMG 145) administered every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on percent change from baseline in LDL-C when used in addition to a…
- Trial name
- LAPLACE (NCT01380730)
- Testing
- Evolocumab
- Where
- 100 sites in United States, Canada and 3 more
- Volunteers
- 631 people
- Sponsor
- Amgen
HIV, Human Immunodeficiency Virus
An Extension of Protocol PRO 140_CD01 Study
This is an extension of Protocol PRO 140_CD 01 to further evaluate the long-term suppression of HIV-1 replication following substitution of stable combination antiretroviral therapy with a PRO 140 (Monoclonal CCR5 antibody)…
- Trial name
- NCT02355184
- Testing
- PRO 140 350mg weekly subcutaneous (SC) injection.
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- CytoDyn, Inc.
Plasmodium Falciparum Infection, Malaria
L9LS MAb in Malian Adults
The purpose of this study is to evaluate the safety and tolerability of a one time SC administration of L9LS in healthy adults in Mali, as well as its protective efficacy against naturally occurring Plasmodium falciparum (Pf)…
- Trial name
- NCT05816330
- Testing
- L9LS (VRC-MALMAB0114-00-AB)
- Where
- 3 sites in Mali
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pancreatic Cancer
Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
This study is to determine the efficacy of bevacizumab and gemcitabine in combination with radiation therapy in the preoperative treatment of potentially-resectable subjects with pancreatic cancer.
- Trial name
- NCT00557492
- Testing
- Avastin (bevacizumab), Gemzar (Gemcitabine), external beam radiotherapy
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Amer Zureikat
Kidney Transplant, Kidney Transplant Recipient
Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
The purpose of this study is to determine whether treatment with rituximab (anti-CD20, Rituxan®, MabThera®) in individuals who develop new anti-HLA antibodies after renal (kidney) transplant will promote longer-term survival of…
- Conditions
- Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
- Trial name
- NCT00307125
- Testing
- Rituximab plus immunosuppression
- Where
- 17 sites in United States
- Volunteers
- 757 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Metastatic Colorectal Cancer
Study of IMC-11F8 in Participants With Colorectal Cancer
The purpose of this study is to determine if IMC-11F8 in combination with chemotherapy is effective in treating colorectal cancer (CRC).
- Trial name
- NCT00835185
- Testing
- IMC-11F8 (necitumumab), Oxaliplatin, Folinic acid (FA)
- Where
- 5 sites in Belgium, Spain
- Volunteers
- 44 people
- Sponsor
- Eli Lilly and Company
Leukaemia, Lymphocytic, Chronic
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
The purpose of this study is to determine whether HuMax-CD20 (ofatumumab) is effective in the treatment of patients failing both fludarabine and alemtuzumab.
- Trial name
- NCT00349349
- Testing
- ofatumumab
- Volunteers
- 223 people
- Sponsor
- GlaxoSmithKline
Graft Versus Host Disease, Steroid Refractory GVHD
Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
Acute Graft Versus Host Disease (GVHD) is a serious medical condition that is a common development after Bone Marrow Transplant (BMT).
- Conditions
- Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease
- Trial name
- NCT01485055
- Testing
- Infliximab and Basiliximab
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Nationwide Children's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.